Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - a randomized parallel-group study
Authors:
- 26 April 2010
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 122 (4) , 295-302
Abstract
To assess efficacy and safety of two dilutions of botulinum neurotoxin type A NT 201 (Xeomin®) in patients with upper limb spasticity of diverse etiology. Changes in functional disability and muscle tone from baseline to week 4 after NT 201 treatment. One hundred ninety-two patients with stroke, brain injury, multiple sclerosis, or cerebral palsy were randomized to either 50 or 20 U/ml NT 201 dilutions. The maximum total NT 201 dose was 495 units. Four weeks post-injection, a ≥ 1-point reduction was observed on the Disability Assessment Scale in 57.1%, and on the Ashworth scale in ≥ 62.2% of patients. The 20 U/ml NT 201 dilution was non-inferior to the 50 U/ml NT 201 dilution. Global improvement was rated high by patients (80.2%) and investigators (89.0%). NT 201 improved functional disability and muscle tone and was well tolerated in patients with upper limb spasticity of diverse etiology in both dilutions.Keywords
This publication has 16 references indexed in Scilit:
- Efficacy and Safety of Botulinum Neurotoxin NT 201 in Poststroke Upper Limb SpasticityClinical Neuropharmacology, 2009
- Botulinum neurotoxins for post‐stroke spasticity in adults: A systematic reviewMovement Disorders, 2009
- European consensus table on the use of botulinum toxin type A in adult spasticityJournal of Rehabilitation Medicine, 2009
- Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): [RETIRED]Neurology, 2008
- Neurophysiological Double-Blind Trial of a Botulinum Neurotoxin Type A Free of Complexing ProteinsClinical Neuropharmacology, 2007
- Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN??) in Focal DystoniaDrugs, 2007
- Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasmJournal of Neural Transmission, 2005
- A new botulinum toxin type A free of complexing proteins for treatment of cervical dystoniaNeurology, 2005
- Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX°) in healthy volunteersJournal of Neural Transmission, 2004
- Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a StrokeNew England Journal of Medicine, 2002